Naproxen/sumatriptan and Alcohol/Food Interactions
There are 6 alcohol/food/lifestyle interactions with naproxen / sumatriptan.
Naproxen Alcohol (Ethanol)
Moderate Drug Interaction
Ask your doctor before using naproxen together with ethanol. Do not drink alcohol while taking naproxen. Alcohol can increase your risk of stomach bleeding caused by naproxen. Call your doctor at once if you have symptoms of bleeding in your stomach or intestines. This includes black, bloody, or tarry stools, or coughing up blood or vomit that looks like coffee grounds. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Sumatriptan High Cholesterol (Hyperlipoproteinemia, Hypertriglyceridemia, Sitosterolemia)
Major Potential Hazard, High plausibility
5-HT1 agonists - CAD risk factors
The group of drugs known as 5-hydroxytryptamine1 receptor (5-HT1) agonists can cause vasospastic reactions, including coronary vasospasm, peripheral vascular ischemia, and colonic ischemia. Rarely, serious adverse cardiac events including acute myocardial infarction, arrhythmia, cardiac arrest, and death have been reported within a few hours following the administration of 5-HT1 agonists, in some cases even in patients with no prior history or findings of coronary artery disease (CAD). Significant elevation in blood pressure, including hypertensive crisis, has also been reported on rare occasions in patients with and without a history of hypertension, as have transient increases in blood pressure and peripheral vascular resistance. In general, patients with potentially unrecognized CAD as predicted by the presence of risk factors (e.g., hypertension, hypercholesterolemia, tobacco use, obesity, diabetes, strong family history of CAD, female with surgical or physiological menopause, or male over 40 years of age) should not be administered 5-HT1 agonists unless a cardiovascular evaluation provides satisfactory clinical evidence indicating the lack of CAD, ischemic heart disease, or other significant underlying cardiovascular disease. As a precaution, the manufacturers recommend that the first dose be administered under medical surveillance in such patients, and that electrocardiographic monitoring be considered during the interval immediately following administration to help detect any asymptomatic cardiac ischemia that may occur. Periodic cardiovascular evaluations should be performed during intermittent, long-term use.
References
- Willett F, Curzen N, Adams J, Armitage M (1992) "Coronary vasospasm induced by subcutaneous sumatriptan." BMJ, 304, p. 1415
- Ottervanger JP, van Witsen TB, Valkenburg HA, Stricker BH (1993) "Postmarketing study of cardiovascular adverse reactions associated with sumatriptan." BMJ, 307, p. 1185
- Curtin T, Brooks AP, Roberts JA (1992) "Cardiorespiratory distress after sumatriptan given by injection." BMJ, 305, d713-4
- Ottervanger JP, Paalman HJ, Boxma GL, Stricker BH (1993) "Transmural myocardial infarction with sumatriptan." Lancet, 341, p. 861-2
- MacLean MR, Smith GC, Templeton AG (1993) "Adverse reactions associated with sumatriptan." Lancet, 341, p. 1092
- Cavazos JE, Caress JB, Chilukuri VR, Devlin T, Gray L, Hurwitz BJ (1994) "Sumatriptan-induced stroke in sagittal sinus thrombosis." Lancet, 343, p. 1105-6
- (2001) "Product Information. Imitrex (sumatriptan)." Glaxo Wellcome
- Plosker GL, Mctavish D (1994) "Sumatriptan - a reappraisal of its pharmacology and therapeutic efficacy in the acute treatment of migraine and cluster headache." Drugs, 47, p. 622-51
- Boyd IW, Rohan AP (1994) "Sumatriptan-induced chest pain." Lancet, 344, p. 1704-5
- Ottervanger JP, Vanwitsen TB, Valkenburg HA, Grobbee DE, Stricker BHC (1994) "Adverse reactions attributed to sumatriptan - a postmarketing study in general practice." Eur J Clin Pharmacol, 47, p. 305-9
- Kelly KM (1995) "Cardiac arrest following use of sumatriptan." Neurology, 45, p. 1211-3
- Mueller L, Gallagher RM, Ciervo CA (1996) "Vasospasm-induced myocardial infarction with sumatriptan." Headache, 36, p. 329-31
- Visser WH, Devriend RHM, Jaspers NMWH, Ferrari MD (1996) "Sumatriptan in clinical practice: a 2-year review of 453 migraine patients." Neurology, 47, p. 46-51
- Visser WH, Jaspers NMWH, Devriend RHM, Ferrari MD (1996) "Chest symptoms after sumatriptan: a two-year clinical practice review in 735 consecutive migraine patients." Cephalalgia, 16, p. 554-9
- (2001) "Product Information. Zomig (zolmitriptan)." Astra-Zeneca Pharmaceuticals
- (2001) "Product Information. Amerge (naratriptan)." Glaxo Wellcome
- (2001) "Product Information. Maxalt (rizatriptan)." Merck & Co., Inc
- Dulli DA (1999) "Naratriptan: an alternative for migraine." Ann Pharmacotherapy, 33, p. 704-11
- Dooley M, Faulds D (1999) "Rizatriptan - A review of its efficacy in the management of migraine." Drugs, 58, p. 699-723
- Morgan DR, Trimble M, McVeigh GE (2000) "Atrial fibrillation associated with sumatriptan." Br Med J, 321, p. 275
- (2001) "Product Information. Axert (almotriptan)." Pharmacia and Upjohn
- (2001) "Product Information. Frova (frovatriptan)." Endo Laboratories LLC
- (2003) "Product Information. Relpax (eletriptan)." Pfizer U.S. Pharmaceuticals
Sumatriptan Obesity
Major Potential Hazard, High plausibility
5-HT1 agonists - CAD risk factors
The group of drugs known as 5-hydroxytryptamine1 receptor (5-HT1) agonists can cause vasospastic reactions, including coronary vasospasm, peripheral vascular ischemia, and colonic ischemia. Rarely, serious adverse cardiac events including acute myocardial infarction, arrhythmia, cardiac arrest, and death have been reported within a few hours following the administration of 5-HT1 agonists, in some cases even in patients with no prior history or findings of coronary artery disease (CAD). Significant elevation in blood pressure, including hypertensive crisis, has also been reported on rare occasions in patients with and without a history of hypertension, as have transient increases in blood pressure and peripheral vascular resistance. In general, patients with potentially unrecognized CAD as predicted by the presence of risk factors (e.g., hypertension, hypercholesterolemia, tobacco use, obesity, diabetes, strong family history of CAD, female with surgical or physiological menopause, or male over 40 years of age) should not be administered 5-HT1 agonists unless a cardiovascular evaluation provides satisfactory clinical evidence indicating the lack of CAD, ischemic heart disease, or other significant underlying cardiovascular disease. As a precaution, the manufacturers recommend that the first dose be administered under medical surveillance in such patients, and that electrocardiographic monitoring be considered during the interval immediately following administration to help detect any asymptomatic cardiac ischemia that may occur. Periodic cardiovascular evaluations should be performed during intermittent, long-term use.
References
- Willett F, Curzen N, Adams J, Armitage M (1992) "Coronary vasospasm induced by subcutaneous sumatriptan." BMJ, 304, p. 1415
- Ottervanger JP, van Witsen TB, Valkenburg HA, Stricker BH (1993) "Postmarketing study of cardiovascular adverse reactions associated with sumatriptan." BMJ, 307, p. 1185
- Curtin T, Brooks AP, Roberts JA (1992) "Cardiorespiratory distress after sumatriptan given by injection." BMJ, 305, d713-4
- Ottervanger JP, Paalman HJ, Boxma GL, Stricker BH (1993) "Transmural myocardial infarction with sumatriptan." Lancet, 341, p. 861-2
- MacLean MR, Smith GC, Templeton AG (1993) "Adverse reactions associated with sumatriptan." Lancet, 341, p. 1092
- Cavazos JE, Caress JB, Chilukuri VR, Devlin T, Gray L, Hurwitz BJ (1994) "Sumatriptan-induced stroke in sagittal sinus thrombosis." Lancet, 343, p. 1105-6
- (2001) "Product Information. Imitrex (sumatriptan)." Glaxo Wellcome
- Plosker GL, Mctavish D (1994) "Sumatriptan - a reappraisal of its pharmacology and therapeutic efficacy in the acute treatment of migraine and cluster headache." Drugs, 47, p. 622-51
- Boyd IW, Rohan AP (1994) "Sumatriptan-induced chest pain." Lancet, 344, p. 1704-5
- Ottervanger JP, Vanwitsen TB, Valkenburg HA, Grobbee DE, Stricker BHC (1994) "Adverse reactions attributed to sumatriptan - a postmarketing study in general practice." Eur J Clin Pharmacol, 47, p. 305-9
- Kelly KM (1995) "Cardiac arrest following use of sumatriptan." Neurology, 45, p. 1211-3
- Mueller L, Gallagher RM, Ciervo CA (1996) "Vasospasm-induced myocardial infarction with sumatriptan." Headache, 36, p. 329-31
- Visser WH, Devriend RHM, Jaspers NMWH, Ferrari MD (1996) "Sumatriptan in clinical practice: a 2-year review of 453 migraine patients." Neurology, 47, p. 46-51
- Visser WH, Jaspers NMWH, Devriend RHM, Ferrari MD (1996) "Chest symptoms after sumatriptan: a two-year clinical practice review in 735 consecutive migraine patients." Cephalalgia, 16, p. 554-9
- (2001) "Product Information. Zomig (zolmitriptan)." Astra-Zeneca Pharmaceuticals
- (2001) "Product Information. Amerge (naratriptan)." Glaxo Wellcome
- (2001) "Product Information. Maxalt (rizatriptan)." Merck & Co., Inc
- Dulli DA (1999) "Naratriptan: an alternative for migraine." Ann Pharmacotherapy, 33, p. 704-11
- Dooley M, Faulds D (1999) "Rizatriptan - A review of its efficacy in the management of migraine." Drugs, 58, p. 699-723
- Morgan DR, Trimble M, McVeigh GE (2000) "Atrial fibrillation associated with sumatriptan." Br Med J, 321, p. 275
- (2001) "Product Information. Axert (almotriptan)." Pharmacia and Upjohn
- (2001) "Product Information. Frova (frovatriptan)." Endo Laboratories LLC
- (2003) "Product Information. Relpax (eletriptan)." Pfizer U.S. Pharmaceuticals
Naproxen High Blood Pressure (Hypertension)
Major Potential Hazard, Moderate plausibility
NSAIDs - fluid retention
Fluid retention and edema have been reported in association with the use of nonsteroidal anti-inflammatory drugs (NSAIDs). Therapy with NSAIDs should be administered cautiously in patients with preexisting fluid retention, hypertension, or a history of heart failure. Blood pressure and cardiovascular status should be monitored closely during the initiation of NSAID treatment and throughout the course of therapy.
References
- (2002) "Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn
- (2002) "Product Information. Nalfon (fenoprofen)." Xspire Pharma
- (2002) "Product Information. Indocin (indomethacin)." Merck & Co., Inc
- (2002) "Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories
- (2002) "Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc
- (2006) "Product Information. Anaprox (naproxen)." Roche Laboratories
- (2001) "Product Information. Clinoril (sulindac)." Merck & Co., Inc
- (2001) "Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical
- (2001) "Product Information. Relafen (nabumetone)." SmithKline Beecham
- (2001) "Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals
- (2001) "Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn
- (2001) "Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories
- (2001) "Product Information. Daypro (oxaprozin)." Searle
- (2001) "Product Information. Mobic (meloxicam)." Boehringer-Ingelheim
Naproxen High Blood Pressure (Hypertension)
Moderate Potential Hazard, Moderate plausibility
naproxen - sodium
Anaprox and Anaprox DS (brands of naproxen sodium) contain 25 mg and 50 mg of sodium per tablet (approximately 1 mEq/250 mg naproxen), respectively, and Naprosyn suspension contains 39 mg per teaspoonful (approximately 1.5 mEq/125 mg naproxen). The sodium content should be considered when these products are used in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.
References
- (2002) "Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc
- (2006) "Product Information. Anaprox (naproxen)." Roche Laboratories
Naproxen High Blood Pressure (Hypertension)
Moderate Potential Hazard, Moderate plausibility
NSAIDs - hypertension
Nonsteroidal anti-inflammatory drugs (NSAIDs), including topicals, can lead to new onset of hypertension or worsening of preexisting hypertension, either of which can contribute to the increased incidence of cardiovascular events. NSAIDs should be used with caution in patients with hypertension. Blood pressure should be monitored closely during the initiation of NSAID therapy and throughout the course of therapy.
References
- (2002) "Product Information. Indocin (indomethacin)." Merck & Co., Inc
- (2002) "Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc
- (2001) "Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals
- (2001) "Product Information. Relafen (nabumetone)." SmithKline Beecham
- (2001) "Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals
- (2001) "Product Information. Dolobid (diflunisal)." Merck & Co., Inc
- (2001) "Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn
- (2001) "Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories
- (2001) "Product Information. Daypro (oxaprozin)." Searle
- (2001) "Product Information. Celebrex (celecoxib)." Searle
- (2012) "Product Information. Meclofenamate Sodium (meclofenamate)." Mylan Pharmaceuticals Inc
- (2016) "Product Information. Flector Patch (diclofenac topical)." Actavis U.S. (Alpharma USPD)
Naproxen/sumatriptan drug interactions
There are 508 drug interactions with naproxen / sumatriptan.
Naproxen/sumatriptan disease interactions
There are 17 disease interactions with naproxen / sumatriptan which include:
- CAD risk factors
- cardiovascular disease
- asthma
- fluid retention
- GI toxicity
- rash
- renal toxicities
- thrombosis
- liver disease
- sodium
- anemia
- heart failure
- hepatotoxicity
- hyperkalemia
- hypertension
- platelet aggregation inhibition
- seizure disorders
More about naproxen / sumatriptan
- naproxen/sumatriptan consumer information
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (99)
- Drug images
- Side effects
- Dosage information
- During pregnancy
- Drug class: antimigraine agents
- En español
Related treatment guides
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.